Close the Gap: Disparities in Cancer Screening Threaten Lives

February marks National Cancer Prevention Month, an initiative to bring awareness to ways Americans can reduce their risk for cancer…

Back to Blog Listing

Sign up to receive the latest updates on Shield^TM

Email address

Please enter a valid email address.

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

Guardant Health press release ECLIPSE trial on ClinicalTrials.gov

Compliance

in real-world clinical settings for colorectal cancer (CRC) screening¹*

Proven accuracy in the pivotal ECLIPSE^† trial, with 83% sensitivity and 90% specificity^2‡§

One of the largest studies and first of its kind to validate a blood test that detects CRC³

The future of CRC screening starts now. Go

*Compliance rate for the first 8,000 patients that were prescribed Shield and completed it.¹

^†The ECLIPSE study (NCT04136002) is comparing the sensitivity and specificity of cfDNA only Shield with findings from subsequent colonoscopy in over 10,000 average-risk patients.^1,2
^‡Specificity detected for advanced neoplasia defined in ECLIPSE as CRC or advanced adenomas.^1,3
^§Patients had no prior diagnosis of CRC, inflammatory bowel disease, or family history of genetic risk for CRC (eg, Lynch syndrome).³

References: 1. Data on file. Guardant Health, Inc. 2. Guardant Health press release. December 15, 2022. 3. ECLIPSE trial on ClinicalTrials.gov

Share this page:

Close the Gap: Disparities in Cancer Screening Threaten Lives

Sign up to receive the latest updates on ShieldTM

Sign up to receive the latest updates on Shield^TM